{
  "id": "fungal-meningitis",
  "title": "Fungal Meningitis",
  "version": "1.1",
  "icd10": [
    "** G02 (Meningitis in other infectious and parasitic diseases classified elsewhere)",
    "B45.1 (Cerebral cryptococcosis)",
    "B38.4 (Coccidioidomycosis meningitis)",
    "B39.4 (Histoplasmosis",
    "unspecified — meningitis)",
    "B37.5 (Candidal meningitis)",
    "B46.1 (Rhinocerebral mucormycosis)"
  ],
  "scope": "** Diagnosis, antifungal treatment, and monitoring of fungal meningitis in adults. Includes cryptococcal meningitis (most common in immunocompromised, especially HIV/AIDS with CD4 <100), coccidioidal meningitis (endemic in southwestern US), histoplasma meningitis (endemic in Ohio/Mississippi River valleys), and other fungal causes (Candida, Aspergillus, Mucorales). Covers induction, consolidation, and maintenance antifungal therapy phases; intracranial pressure management including serial therapeutic lumbar punctures; and immune reconstitution inflammatory syndrome (IRIS) management in HIV patients. Excludes bacterial meningitis (see Bacterial Meningitis template), viral meningitis, TB meningitis, and pediatric fungal meningitis.",
  "notes": [],
  "sections": {
    "Laboratory Workup": {
      "Essential/Core Labs": [
        {
          "item": "CBC with differential (CPT 85025)",
          "rationale": "Baseline; leukopenia in immunocompromised; pancytopenia from disseminated fungal infection; pre-treatment baseline for flucytosine (myelosuppressive)",
          "target": "Normal; document baseline for monitoring",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "CMP (BMP + LFTs) (CPT 80053)",
          "rationale": "Renal function critical for amphotericin B dosing (nephrotoxic); hepatic function for azole dosing; electrolytes (hypokalemia and hypomagnesemia from amphotericin B)",
          "target": "Normal; baseline Cr, K, Mg, LFTs",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Magnesium (CPT 83735)",
          "rationale": "Amphotericin B causes renal magnesium wasting; must supplement aggressively",
          "target": "Normal (1.8-2.4 mg/dL)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Phosphorus (CPT 84100)",
          "rationale": "Amphotericin B causes renal electrolyte wasting",
          "target": "Normal",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Blood cultures x2 (different sites) (CPT 87040)",
          "rationale": "Fungemia detection; Cryptococcus can be cultured from blood in disseminated disease",
          "target": "No growth",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Blood cultures — fungal (CPT 87103)",
          "rationale": "Fungal blood cultures have higher yield for Histoplasma and Candida; use lysis-centrifugation method (Isolator) if available",
          "target": "No growth",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Serum cryptococcal antigen (CrAg) — lateral flow assay (CPT 87327)",
          "rationale": "Highly sensitive (>99%) and specific (>97%) for cryptococcal disease; positive in both serum and CSF; can quantify for treatment monitoring; serum CrAg positive in >99% of HIV-associated cryptococcal meningitis",
          "target": "Negative; if positive, report titer",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "HIV 1/2 antigen/antibody (4th generation) (CPT 87389)",
          "rationale": "MANDATORY — cryptococcal meningitis is an AIDS-defining illness; CD4 count determines treatment approach and ART timing; all patients with fungal meningitis need HIV testing",
          "target": "Negative; if positive, obtain CD4 and viral load",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "CD4 count and HIV viral load (if HIV positive) (CPT 86360+87536)",
          "rationale": "CD4 <100 cells/microL is highest risk for cryptococcal meningitis; guides ART initiation timing (delay 4-6 weeks in crypto to prevent IRIS)",
          "target": "CD4 >200 cells/microL",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Procalcitonin (CPT 84145)",
          "rationale": "Low procalcitonin helps exclude bacterial meningitis; typically low in fungal infection",
          "target": "Low (<0.5 ng/mL suggests non-bacterial)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "CRP (CPT 86140)",
          "rationale": "Inflammatory marker; typically mildly elevated in fungal meningitis compared to bacterial",
          "target": "Mild elevation",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Lactate (serum) (CPT 83605)",
          "rationale": "Sepsis assessment; monitor hemodynamic status",
          "target": "<2 mmol/L",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Coagulation panel (PT/INR, aPTT) (CPT 85610+85730)",
          "rationale": "Pre-LP coagulopathy assessment; DIC screen in sepsis",
          "target": "Normal",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Blood glucose (paired with LP) (CPT 82947)",
          "rationale": "Required to calculate CSF:serum glucose ratio; low CSF glucose is hallmark of fungal meningitis",
          "target": "Paired with CSF glucose",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Type and screen (CPT 86900)",
          "rationale": "Potential need for blood products; amphotericin B infusion reactions",
          "target": "On file",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "STAT"
        }
      ],
      "Extended Workup (Second-line)": [
        {
          "item": "1,3-Beta-D-glucan (serum) (CPT 87449)",
          "rationale": "Panfungal biomarker; elevated in most invasive fungal infections EXCEPT Cryptococcus and Mucorales (which do not produce beta-D-glucan); sensitivity ~77% for invasive fungal disease",
          "target": "Negative (<60 pg/mL); elevated suggests non-Cryptococcus fungal infection",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Galactomannan (serum) (CPT 87305)",
          "rationale": "Aspergillus-specific antigen; sensitivity higher in neutropenic patients; consider if immunocompromised with pulmonary and CNS disease",
          "target": "Negative (index <0.5)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Coccidioides serology — IgM and IgG (EIA + immunodiffusion) (CPT 86635)",
          "rationale": "Coccidioidomycosis screening; complement fixation (CF) titer in CSF is diagnostic of coccidioidal meningitis; serum IgM positive early in infection",
          "target": "Negative; if positive, obtain complement fixation titer",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Coccidioides complement fixation (CF) titer — serum (CPT 86635)",
          "rationale": "Quantitative titer correlates with disease severity; rising titers indicate active disease; declining titers suggest treatment response",
          "target": "Negative; if positive, titers >1:16 suggest disseminated disease",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Histoplasma antigen (urine and serum) (CPT 87385)",
          "rationale": "Highly sensitive for disseminated histoplasmosis (>90% urine sensitivity in disseminated disease); less sensitive in meningitis alone (~50% in CSF)",
          "target": "Negative",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Histoplasma antibody (complement fixation and immunodiffusion)",
          "rationale": "Antibody detection; may be negative in immunocompromised; seroconversion takes 2-6 weeks",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Serum osmolality (CPT 83930)",
          "rationale": "SIADH assessment (common with CNS infections); monitor with amphotericin B",
          "target": "280-295 mOsm/kg",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "Urine osmolality and sodium",
          "rationale": "SIADH confirmation if hyponatremia present",
          "target": "Evaluate if hyponatremic",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "Quantitative immunoglobulins (IgG, IgA, IgM) (CPT 82784+82785+82787)",
          "rationale": "Identify underlying humoral immunodeficiency predisposing to fungal infections",
          "target": "Normal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "T-cell subsets (CD4/CD8 ratio) (CPT 86360)",
          "rationale": "Cellular immunodeficiency assessment if HIV-negative; low CD4 from other causes (transplant, steroids, malignancy) increases risk",
          "target": "Normal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Rare/Specialized (Refractory or Atypical)": [
        {
          "item": "Metagenomic next-generation sequencing (mNGS) of CSF",
          "rationale": "Culture-negative chronic meningitis; identifies unexpected or rare fungal pathogens; high sensitivity for organisms that are difficult to culture",
          "target": "Pathogen identification",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "EXT"
        },
        {
          "item": "Aspergillus PCR (CSF)",
          "rationale": "Suspected CNS aspergillosis; more sensitive than culture; immunocompromised with pulmonary and CNS disease",
          "target": "Negative",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "-",
          "ICU": "EXT"
        },
        {
          "item": "Mucorales PCR or tissue biopsy",
          "rationale": "Rhinocerebral mucormycosis suspicion; diabetic ketoacidosis, neutropenia, iron overload",
          "target": "Negative",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "-",
          "ICU": "EXT"
        },
        {
          "item": "Blastomyces antigen (urine) (CPT 87385)",
          "rationale": "Blastomycosis in endemic areas (Great Lakes, Ohio/Mississippi River valleys); rare CNS involvement",
          "target": "Negative",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-"
        },
        {
          "item": "RPR/VDRL (serum) (CPT 86592)",
          "rationale": "Neurosyphilis in chronic meningitis differential",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "QuantiFERON-TB Gold (CPT 86480)",
          "rationale": "TB meningitis in differential (subacute, basilar, immunocompromised); CSF profile similar to fungal",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "ACE level (serum) (CPT 82164)",
          "rationale": "Neurosarcoidosis in chronic meningitis differential",
          "target": "Normal",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Toxoplasma IgG/IgM (CPT 86777+86778)",
          "rationale": "Toxoplasmosis in HIV/immunocompromised patients",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Strongyloides antibody (CPT 86682)",
          "rationale": "Hyperinfection risk if immunosuppression planned; eosinophilic meningitis differential",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Lumbar Puncture": [
        {
          "item": "Opening pressure (manometry)",
          "rationale": "Elevated ICP is common in cryptococcal meningitis (>60-70% have OP >20 cm H2O); elevated ICP is the primary driver of mortality; guides need for serial therapeutic LPs",
          "target": "Normal 10-20 cm H2O; cryptococcal meningitis often 25-50+ cm H2O; >25 cm H2O requires therapeutic drainage",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Cell count with differential (tubes 1 AND 4) (CPT 89051)",
          "rationale": "Lymphocytic pleocytosis typical of fungal meningitis; WBC count may be low in severe immunosuppression (HIV/AIDS) — paucicellular CSF with positive CrAg indicates poor prognosis",
          "target": "WBC 20-500 cells/microL, predominantly lymphocytes; may be <20 in severely immunocompromised",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Protein (CPT 84157)",
          "rationale": "Elevated in fungal meningitis (50-500 mg/dL); very high protein (>500) suggests basilar arachnoiditis (Coccidioides) or CSF block",
          "target": "Elevated (typically 50-200 mg/dL in Cryptococcus; higher in Coccidioides)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Glucose with paired serum glucose (CPT 82945)",
          "rationale": "Low CSF glucose is hallmark of fungal meningitis; CSF:serum ratio <0.4",
          "target": "Low (<40 mg/dL); CSF:serum ratio <0.5 (often <0.4)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "CSF cryptococcal antigen (CrAg) — lateral flow assay (CPT 87327)",
          "rationale": "GOLD STANDARD rapid diagnostic test for cryptococcal meningitis; sensitivity >98%, specificity >99% in CSF; quantitative titers correlate with fungal burden; serial titers monitor treatment response",
          "target": "Negative; if positive, report titer (high titers e.g. >1:1024 indicate high fungal burden and worse prognosis)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "India ink preparation (CPT 87205)",
          "rationale": "Classic rapid test showing encapsulated yeast; sensitivity only 50-70% (lower in non-HIV); largely replaced by CrAg but may be diagnostic if CrAg unavailable",
          "target": "Encapsulated yeast (budding yeast with clear halo); negative does NOT exclude diagnosis",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Fungal culture (CPT 87102)",
          "rationale": "Gold standard for organism identification (grows in 3-7 days for Cryptococcus, longer for others); required for speciation and antifungal susceptibility testing; positive in 75-90% of cryptococcal meningitis",
          "target": "No growth; if positive — speciation and susceptibility testing",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Gram stain (CPT 87205)",
          "rationale": "Exclude concurrent bacterial meningitis",
          "target": "No organisms",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Bacterial culture and sensitivity (CPT 87070)",
          "rationale": "Exclude concurrent bacterial meningitis, especially in immunocompromised",
          "target": "No growth",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "BioFire FilmArray Meningitis/Encephalitis Panel (CPT 87483)",
          "rationale": "Rapid multiplex PCR (~1 hour); detects Cryptococcus neoformans/gattii plus 13 other pathogens; useful for rapid differentiation from bacterial and viral causes",
          "target": "Cryptococcus detected or negative; rules out concurrent bacterial/viral pathogens",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "CSF lactate (CPT 83605)",
          "rationale": "Elevated in bacterial (>3.5) but variable in fungal; helps distinguish from bacterial meningitis",
          "target": "Variable in fungal (often 2.5-4.0 mmol/L); elevated >3.5 more suggestive of bacterial",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Coccidioides complement fixation (CF) — CSF (CPT 86635)",
          "rationale": "Diagnostic of coccidioidal meningitis; CSF CF titer almost always positive in Coccidioides meningitis; declining CSF titers indicate treatment response",
          "target": "Negative; if positive, report titer (any positive CSF CF titer is diagnostic)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Histoplasma antigen — CSF (CPT 87385)",
          "rationale": "Moderate sensitivity (~50%) in Histoplasma meningitis; higher in disseminated disease",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "AFB smear and culture (CPT 87116)",
          "rationale": "TB meningitis has identical CSF profile; must exclude in any chronic lymphocytic meningitis, especially immunocompromised or endemic area",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Cytology (CPT 88104)",
          "rationale": "Leptomeningeal carcinomatosis in chronic meningitis differential",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "VDRL — CSF (CPT 86592)",
          "rationale": "Neurosyphilis screen in chronic meningitis differential",
          "target": "Negative",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "HSV 1/2 PCR (CPT 87529)",
          "rationale": "Exclude HSV encephalitis if fever with altered mental status",
          "target": "Negative",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "STAT"
        }
      ]
    },
    "Imaging & Studies": {
      "Essential/First-line": [
        {
          "item": "CT head without contrast (CPT 70450)",
          "timing": "Immediate — before LP to exclude mass effect; obtain in all patients with altered mental status, focal deficits, papilledema, immunocompromised state",
          "target": "Hydrocephalus (common in cryptococcal meningitis); mass lesion (cryptococcoma, abscess); basilar meningeal enhancement is NOT seen on non-contrast CT",
          "contraindications": "Pregnancy (relative)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "MRI brain with and without contrast (CPT 70553)",
          "timing": "Within 24-48h; STAT if focal deficits or altered consciousness",
          "target": "Leptomeningeal enhancement (especially basilar); cryptococcomas (gelatinous pseudocysts in basal ganglia/midbrain); dilated perivascular spaces (Virchow-Robin spaces); hydrocephalus; ring-enhancing lesions (Aspergillus abscess); basilar arachnoiditis (Coccidioides, Histoplasma)",
          "contraindications": "Pacemaker; metallic implants",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Chest X-ray (CPT 71046)",
          "timing": "Within first hours",
          "target": "Pulmonary nodules, cavitary lesions, hilar lymphadenopathy (Histoplasma, Coccidioides); Aspergillus — halo sign; disseminated cryptococcal disease",
          "contraindications": "None significant",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        }
      ],
      "Extended": [
        {
          "item": "CT chest (CPT 71260)",
          "timing": "Within 48h if chest X-ray abnormal or pulmonary source suspected",
          "target": "Pulmonary cryptococcal nodules; coccidioidal cavitary disease; Aspergillus halo sign or air-crescent sign; hilar/mediastinal lymphadenopathy (Histoplasma)",
          "contraindications": "Contrast allergy; renal impairment",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "MRI spine with contrast (CPT 72156)",
          "timing": "If spinal symptoms, radiculopathy, or myelopathy",
          "target": "Arachnoiditis (especially Coccidioides — involves spinal arachnoid); spinal cord compression; epidural abscess",
          "contraindications": "Pacemaker; metallic implants",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "CT sinuses (CPT 70486)",
          "timing": "If rhinocerebral mucormycosis suspected; facial pain, periorbital swelling, black eschar in diabetic or neutropenic patient",
          "target": "Sinus opacification; bony erosion; orbital extension",
          "contraindications": "None significant",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "CT angiography head (CTA) (CPT 70496)",
          "timing": "If vasculitis or vascular complications suspected (Aspergillus, Mucorales are angioinvasive)",
          "target": "Vessel irregularity; stenosis; aneurysm (mycotic); vascular occlusion",
          "contraindications": "Contrast allergy; renal impairment",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "MRA brain (CPT 70544)",
          "timing": "Non-contrast alternative for vascular assessment",
          "target": "Vessel irregularity; stenosis; aneurysm (mycotic); vascular occlusion",
          "contraindications": "Pacemaker; metallic implants",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Continuous EEG (CPT 95700)",
          "timing": "If altered mental status out of proportion to imaging; suspected non-convulsive seizures",
          "target": "Seizure activity; non-convulsive status epilepticus; diffuse slowing",
          "contraindications": "None significant",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "STAT"
        }
      ],
      "Rare/Specialized": [
        {
          "item": "Brain biopsy (stereotactic)",
          "timing": "If diagnosis unclear despite full workup; ring-enhancing lesion of unknown etiology; suspected Aspergillus or Mucorales abscess",
          "target": "Fungal elements on histopathology (GMS and PAS staining); culture identification",
          "contraindications": "Coagulopathy; inaccessible location; surgical risk",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "-",
          "ICU": "EXT"
        },
        {
          "item": "Nasal/sinus biopsy",
          "timing": "Suspected rhinocerebral mucormycosis; tissue diagnosis essential for Mucorales",
          "target": "Broad non-septate hyphae with right-angle branching (mucormycosis); angioinvasion",
          "contraindications": "Coagulopathy",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "CT myelogram (CPT 62284+72132)",
          "timing": "Suspected arachnoiditis with spinal cord compromise; MRI contraindicated",
          "target": "Arachnoid adhesions; CSF flow obstruction; communicating hydrocephalus",
          "contraindications": "Contrast allergy; coagulopathy",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "-",
          "ICU": "EXT"
        }
      ]
    },
    "Treatment": {
      "Acute/Emergent — Induction Therapy (Cryptococcal Meningitis)": [
        {
          "item": "Amphotericin B liposomal (AmBisome)",
          "route": "IV",
          "indication": "First-line induction therapy for cryptococcal meningitis; fungicidal; liposomal formulation preferred over conventional due to reduced nephrotoxicity",
          "dosing": {
            "doseOptions": [
              {
                "text": "3-4 mg/kg/day",
                "orderSentence": "Amphotericin B liposomal (AmBisome) 3-4 mg/kg/day IV"
              }
            ],
            "route": "IV",
            "instructions": "3-4 mg/kg IV daily for minimum 2 weeks (induction); infuse over 2 hours; premedicate with acetaminophen, diphenhydramine, and normal saline 500 mL before each dose to reduce infusion reactions and nephrotoxicity",
            "orderSentence": "Amphotericin B liposomal (AmBisome) 3-4 mg/kg/day IV"
          },
          "contraindications": "Severe renal impairment (dose adjust or switch formulation); anaphylaxis to amphotericin; concurrent nephrotoxic agents (minimize)",
          "monitoring": "Renal function (BMP daily); potassium and magnesium twice daily during induction; CBC twice weekly; LFTs weekly; infusion reaction monitoring",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Amphotericin B conventional (deoxycholate)",
          "route": "IV",
          "indication": "Alternative induction if liposomal formulation unavailable; higher nephrotoxicity but more widely available globally (WHO preferred in resource-limited settings)",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.7-1.0 mg/kg/day",
                "orderSentence": "Amphotericin B conventional (deoxycholate) 0.7-1.0 mg/kg/day IV"
              }
            ],
            "route": "IV",
            "instructions": "0.7-1.0 mg/kg IV daily for minimum 2 weeks; infuse over 4-6 hours; aggressive normal saline pre-hydration (1L before each dose)",
            "orderSentence": "Amphotericin B conventional (deoxycholate) 0.7-1.0 mg/kg/day IV"
          },
          "contraindications": "Severe renal impairment; concomitant nephrotoxins",
          "monitoring": "Renal function daily; potassium and magnesium twice daily; CBC twice weekly; rigors, fever during infusion",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Flucytosine (5-FC, Ancobon)",
          "route": "PO",
          "indication": "Combination with amphotericin B for induction; improves fungal clearance and reduces relapse; synergistic with amphotericin B",
          "dosing": {
            "doseOptions": [
              {
                "text": "25 mg/kg",
                "orderSentence": "Flucytosine (5-FC, Ancobon) 25 mg/kg PO"
              }
            ],
            "route": "PO",
            "instructions": "25 mg/kg PO q6h (100 mg/kg/day in 4 divided doses) for 2 weeks; adjust for renal function (GFR-based dosing); take with food to reduce GI side effects",
            "orderSentence": "Flucytosine (5-FC, Ancobon) 25 mg/kg PO"
          },
          "contraindications": "Severe hepatic impairment; bone marrow suppression; pregnancy (teratogenic, Category C)",
          "monitoring": "CBC with differential twice weekly (myelosuppression — leukopenia, thrombocytopenia); LFTs weekly; flucytosine drug levels if available (target peak 30-80 mcg/mL; toxic >100); renal function daily (adjust dose with declining GFR)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Fluconazole (high-dose induction alternative)",
          "route": "PO/IV",
          "indication": "Alternative induction when amphotericin B or flucytosine unavailable (WHO alternative regimen); inferior to amphotericin-based regimens but used in resource-limited settings",
          "dosing": {
            "doseOptions": [
              {
                "text": "1200 mg",
                "orderSentence": "Fluconazole (high-dose induction alternative) 1200 mg PO/IV"
              }
            ],
            "route": "PO/IV",
            "instructions": "1200 mg PO or IV daily for 2 weeks (induction); used with flucytosine if amphotericin B unavailable",
            "orderSentence": "Fluconazole (high-dose induction alternative) 1200 mg PO/IV"
          },
          "contraindications": "Severe hepatic impairment; QT prolongation; concurrent QT-prolonging medications; pregnancy (teratogenic in first trimester at high doses)",
          "monitoring": "LFTs weekly; QTc at baseline and weekly; drug interactions (CYP2C9, CYP3A4 inhibitor)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        }
      ],
      "Symptomatic Treatments": [
        {
          "item": "Normal saline pre-hydration",
          "route": "IV",
          "indication": "Nephroprotection during amphotericin B therapy; prevents amphotericin-induced renal vasoconstriction",
          "dosing": {
            "doseOptions": [
              {
                "text": "500-1000 mL",
                "orderSentence": "Normal saline pre-hydration 500-1000 mL IV"
              }
            ],
            "route": "IV",
            "instructions": "500-1000 mL IV normal saline infused before each amphotericin B dose",
            "orderSentence": "Normal saline pre-hydration 500-1000 mL IV"
          },
          "contraindications": "Volume overload; decompensated heart failure",
          "monitoring": "I/O; weight; electrolytes; signs of volume overload",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Potassium chloride supplementation",
          "route": "IV/PO",
          "indication": "Amphotericin B causes renal potassium wasting in >80% of patients; severe hypokalemia can cause cardiac arrhythmias",
          "dosing": {
            "doseOptions": [
              {
                "text": "20-40 mEq",
                "orderSentence": "Potassium chloride supplementation 20-40 mEq IV/PO"
              }
            ],
            "route": "IV/PO",
            "instructions": "Replace per institutional protocol; target K >3.5 mEq/L; oral preferred if tolerated; IV replacement for K <3.0 or symptomatic",
            "orderSentence": "Potassium chloride supplementation 20-40 mEq IV/PO"
          },
          "contraindications": "Hyperkalemia; renal failure (use cautiously)",
          "monitoring": "Potassium levels twice daily during induction; ECG if K <3.0 or >5.5",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Magnesium supplementation",
          "route": "IV/PO",
          "indication": "Amphotericin B causes renal magnesium wasting; hypomagnesemia worsens hypokalemia (refractory hypokalemia until Mg corrected)",
          "dosing": {
            "doseOptions": [
              {
                "text": "2-4 g",
                "orderSentence": "Magnesium supplementation 2-4 g IV"
              }
            ],
            "route": "IV",
            "instructions": "Magnesium sulfate 2-4 g IV over 2-4 hours for Mg <1.5; oral magnesium oxide 400-800 mg daily for mild depletion",
            "orderSentence": "Magnesium supplementation 2-4 g IV"
          },
          "contraindications": "Renal failure (use cautiously); heart block",
          "monitoring": "Magnesium levels daily during induction; renal function",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Acetaminophen (amphotericin premedication)",
          "route": "PO/IV",
          "indication": "Prevents infusion-related fever and rigors during amphotericin B administration",
          "dosing": {
            "doseOptions": [
              {
                "text": "650-1000 mg",
                "orderSentence": "Acetaminophen (amphotericin premedication) 650-1000 mg PO/IV"
              }
            ],
            "route": "PO/IV",
            "instructions": "650-1000 mg PO or IV 30-60 minutes before each amphotericin B infusion; max 4 g/day",
            "orderSentence": "Acetaminophen (amphotericin premedication) 650-1000 mg PO/IV"
          },
          "contraindications": "Severe hepatic impairment",
          "monitoring": "LFTs; hepatic function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "Diphenhydramine (amphotericin premedication)",
          "route": "IV",
          "indication": "Prevents infusion-related allergic reactions during amphotericin B",
          "dosing": {
            "doseOptions": [
              {
                "text": "25-50 mg",
                "orderSentence": "Diphenhydramine (amphotericin premedication) 25-50 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "25-50 mg IV 30-60 minutes before each amphotericin B infusion",
            "orderSentence": "Diphenhydramine (amphotericin premedication) 25-50 mg IV"
          },
          "contraindications": "Narrow-angle glaucoma; urinary retention",
          "monitoring": "Sedation level",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "Meperidine",
          "route": "IV",
          "indication": "Treatment of amphotericin B-related rigors unresponsive to acetaminophen premedication",
          "dosing": {
            "doseOptions": [
              {
                "text": "25-50 mg",
                "orderSentence": "Meperidine 25-50 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "25-50 mg IV PRN for rigors during amphotericin B infusion; avoid repeated dosing (normeperidine accumulation)",
            "orderSentence": "Meperidine 25-50 mg IV"
          },
          "contraindications": "Seizure history (lowers threshold); MAOI use; renal failure (normeperidine accumulation)",
          "monitoring": "Sedation; seizure risk; renal function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "Acetazolamide",
          "route": "PO",
          "indication": "Adjunctive ICP reduction in fungal meningitis with persistent mildly elevated ICP after therapeutic LPs; reduces CSF production",
          "dosing": {
            "doseOptions": [
              {
                "text": "250 mg",
                "orderSentence": "Acetazolamide 250 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "250 mg PO BID-TID; titrate to 500 mg TID if tolerated; monitor for metabolic acidosis and paresthesias",
            "orderSentence": "Acetazolamide 250 mg PO"
          },
          "contraindications": "Severe hepatic or renal impairment; sulfonamide allergy; hyponatremia; metabolic acidosis",
          "monitoring": "BMP (bicarbonate, potassium); symptoms of metabolic acidosis; paresthesias",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Mannitol 20%",
          "route": "IV",
          "indication": "Acute elevated ICP with signs of herniation (declining consciousness, pupil asymmetry); bridge to therapeutic LP or VP shunt",
          "dosing": {
            "doseOptions": [
              {
                "text": "1-1.5 g/kg",
                "orderSentence": "Mannitol 20% 1-1.5 g/kg IV"
              }
            ],
            "route": "IV",
            "instructions": "1-1.5 g/kg IV bolus; then 0.25-0.5 g/kg q4-6h; maintain serum osmolality <320 mOsm/kg",
            "orderSentence": "Mannitol 20% 1-1.5 g/kg IV"
          },
          "contraindications": "Anuria; severe dehydration",
          "monitoring": "Serum osmolality; osmolar gap; renal function; I/O",
          "ED": "STAT",
          "HOSP": "-",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Levetiracetam",
          "route": "IV/PO",
          "indication": "Seizure management if seizures occur; NOT routine prophylaxis; lower drug interaction profile than phenytoin (important with azoles)",
          "dosing": {
            "doseOptions": [
              {
                "text": "1000-1500 mg",
                "orderSentence": "Levetiracetam 1000-1500 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "1000-1500 mg IV or PO BID; load 1000-1500 mg if acute seizure; max 3000 mg/day",
            "orderSentence": "Levetiracetam 1000-1500 mg IV"
          },
          "contraindications": "Severe renal impairment (dose adjust)",
          "monitoring": "Renal function; mood and behavioral changes",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Ondansetron",
          "route": "IV/PO",
          "indication": "Nausea and vomiting from elevated ICP, medications (flucytosine, azoles), or meningeal irritation",
          "dosing": {
            "doseOptions": [
              {
                "text": "4 mg",
                "orderSentence": "Ondansetron 4 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "4 mg IV or PO q6h PRN nausea; max 16 mg/day",
            "orderSentence": "Ondansetron 4 mg IV"
          },
          "contraindications": "QT prolongation",
          "monitoring": "QTc if concurrent QT-prolonging agents",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Dexamethasone",
          "route": "IV",
          "indication": "IRIS management in HIV patients who develop worsening symptoms after ART initiation; NOT recommended as routine adjunct in cryptococcal meningitis (unlike bacterial meningitis — dexamethasone INCREASED mortality in cryptococcal meningitis per ACTA trial)",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.3 mg/kg/day",
                "orderSentence": "Dexamethasone 0.3 mg/kg/day IV"
              }
            ],
            "route": "IV",
            "instructions": "0.3 mg/kg/day IV (or equivalent) for IRIS only; taper over 2-6 weeks based on clinical response; use ONLY for IRIS, NOT for routine cryptococcal meningitis",
            "orderSentence": "Dexamethasone 0.3 mg/kg/day IV"
          },
          "contraindications": "Active untreated infection; GI bleeding; uncontrolled diabetes",
          "monitoring": "Glucose q6h; GI prophylaxis; BP; signs of infection progression",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "Pantoprazole",
          "route": "IV/PO",
          "indication": "GI prophylaxis during steroid therapy for IRIS; stress ulcer prevention in ICU",
          "dosing": {
            "doseOptions": [
              {
                "text": "40 mg",
                "orderSentence": "Pantoprazole 40 mg IV/PO"
              }
            ],
            "route": "IV/PO",
            "instructions": "40 mg IV or PO daily",
            "orderSentence": "Pantoprazole 40 mg IV/PO"
          },
          "contraindications": "Prolonged use risks (C. difficile, hypomagnesemia)",
          "monitoring": "GI symptoms",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        },
        {
          "item": "Enoxaparin",
          "route": "SC",
          "indication": "DVT prophylaxis in hospitalized patients with prolonged immobility",
          "dosing": {
            "doseOptions": [
              {
                "text": "40 mg",
                "orderSentence": "Enoxaparin 40 mg SC"
              }
            ],
            "route": "SC",
            "instructions": "40 mg SC daily; start when no active coagulopathy",
            "orderSentence": "Enoxaparin 40 mg SC"
          },
          "contraindications": "Active bleeding; thrombocytopenia (<50K); coagulopathy",
          "monitoring": "Platelets; coagulation studies",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        }
      ],
      "Second-line/Refractory": [
        {
          "item": "Voriconazole",
          "route": "IV/PO",
          "indication": "Aspergillus meningitis (first-line for CNS aspergillosis); second-line for resistant Cryptococcus; good CNS penetration",
          "dosing": {
            "doseOptions": [
              {
                "text": "6 mg/kg IV q12h x2 doses (load)",
                "orderSentence": "Voriconazole 6 mg/kg IV q12h x2 doses (load) IV"
              },
              {
                "text": "4 mg/kg IV q12h",
                "orderSentence": "Voriconazole 4 mg/kg IV q12h IV"
              }
            ],
            "route": "IV",
            "instructions": "Load: 6 mg/kg IV q12h for 2 doses; Maintenance: 4 mg/kg IV q12h (switch to PO 200-300 mg BID when stable); target trough 2-5.5 mcg/mL",
            "orderSentence": "Voriconazole 6 mg/kg IV q12h x2 doses (load) IV"
          },
          "contraindications": "Severe hepatic impairment; co-administration with sirolimus, rifampin, carbamazepine, phenobarbital; IV formulation contains cyclodextrin — avoid in renal impairment (GFR <50)",
          "monitoring": "Trough levels (target 2-5.5 mcg/mL); LFTs weekly; visual disturbance assessment; dermatologic monitoring (photosensitivity, squamous cell carcinoma with prolonged use); drug interactions (CYP2C19, 2C9, 3A4)",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Isavuconazole (Cresemba)",
          "route": "IV/PO",
          "indication": "Alternative to voriconazole for CNS aspergillosis; better tolerated; fewer drug interactions; does NOT require cyclodextrin (safe in renal impairment)",
          "dosing": {
            "doseOptions": [
              {
                "text": "200 mg",
                "orderSentence": "Isavuconazole (Cresemba) 200 mg IV/PO"
              }
            ],
            "route": "IV/PO",
            "instructions": "Loading: 200 mg IV or PO q8h for 6 doses (48 hours); Maintenance: 200 mg IV or PO daily",
            "orderSentence": "Isavuconazole (Cresemba) 200 mg IV/PO"
          },
          "contraindications": "Severe hepatic impairment; familial short QT syndrome; concurrent strong CYP3A4 inducers",
          "monitoring": "LFTs weekly; hepatotoxicity monitoring; drug interactions (CYP3A4)",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Itraconazole",
          "route": "PO",
          "indication": "Alternative for Histoplasma meningitis (after amphotericin B induction); second-line for Coccidioides meningitis; requires acidic gastric pH for absorption",
          "dosing": {
            "doseOptions": [
              {
                "text": "200 mg",
                "orderSentence": "Itraconazole 200 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "200 mg PO BID-TID (solution preferred over capsules for better absorption); target trough >1.0 mcg/mL; take solution on empty stomach, capsules with food",
            "orderSentence": "Itraconazole 200 mg PO"
          },
          "contraindications": "Severe hepatic impairment; ventricular dysfunction (negative inotrope); concurrent CYP3A4 substrates",
          "monitoring": "Trough levels (target >1.0 mcg/mL); LFTs weekly initially then monthly; monitor for heart failure symptoms; drug interactions",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Posaconazole",
          "route": "PO",
          "indication": "Salvage therapy for refractory Aspergillus or Mucorales CNS infection; delayed-release tablets preferred",
          "dosing": {
            "doseOptions": [
              {
                "text": "300 mg",
                "orderSentence": "Posaconazole 300 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Loading: 300 mg PO BID on day 1; Maintenance: 300 mg PO daily; delayed-release tablets preferred (consistent absorption)",
            "orderSentence": "Posaconazole 300 mg PO"
          },
          "contraindications": "Severe hepatic impairment; QT prolongation",
          "monitoring": "Trough levels (target >1.0 mcg/mL for prophylaxis; >1.5 for treatment); LFTs; QTc; drug interactions",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Intrathecal amphotericin B",
          "route": "IT",
          "indication": "Refractory coccidioidal meningitis not responding to systemic azoles; rarely used due to toxicity; specialist administration only",
          "dosing": {
            "doseOptions": [
              {
                "text": "0.01-0.5 mg",
                "orderSentence": "Intrathecal amphotericin B 0.01-0.5 mg IT"
              }
            ],
            "route": "IT",
            "instructions": "Start 0.01 mg IT; titrate slowly to 0.5 mg as tolerated over weeks; administered via LP or Ommaya reservoir; mix with CSF and inject slowly",
            "orderSentence": "Intrathecal amphotericin B 0.01-0.5 mg IT"
          },
          "contraindications": "Coagulopathy; infection at injection site",
          "monitoring": "Chemical arachnoiditis symptoms (headache, nausea, radiculopathy); neurological exam after each dose; CSF analysis",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "EXT"
        },
        {
          "item": "VP shunt or lumbar drain",
          "route": "Surgical",
          "indication": "Refractory elevated ICP despite daily therapeutic LPs for >1 week; progressive hydrocephalus; clinical deterioration from ICP",
          "dosing": {
            "doseOptions": [
              {
                "text": "N/A",
                "orderSentence": "VP shunt or lumbar drain N/A Surgical"
              }
            ],
            "route": "Surgical",
            "instructions": "Neurosurgical placement; VP shunt with programmable valve preferred",
            "orderSentence": "VP shunt or lumbar drain N/A Surgical"
          },
          "contraindications": "Active ventriculitis (relative); coagulopathy (correct first)",
          "monitoring": "Shunt function; ICP; imaging for shunt position; signs of shunt infection/malfunction",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT"
        }
      ],
      "Disease-Modifying/Chronic Therapies — Consolidation and Maintenance": [
        {
          "item": "Fluconazole (consolidation phase)",
          "route": "PO",
          "indication": "Consolidation therapy after successful 2-week induction (Cryptococcus); transition from IV amphotericin B when CSF is sterilizing; 8 weeks consolidation",
          "dosing": {
            "doseOptions": [
              {
                "text": "400 mg",
                "orderSentence": "Fluconazole (consolidation phase) 400 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "400 mg PO daily for 8 weeks (consolidation); begin after minimum 2-week induction and clinical improvement",
            "orderSentence": "Fluconazole (consolidation phase) 400 mg PO"
          },
          "pretreatment": "Confirm negative or declining CSF fungal culture at end of induction; clinical improvement; able to take oral medication",
          "contraindications": "Severe hepatic impairment; QT prolongation; pregnancy (teratogenic); concurrent QT-prolonging medications",
          "monitoring": "LFTs at 2 weeks then monthly; QTc if risk factors; drug interactions (CYP2C9, CYP3A4 inhibitor); clinical response",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Fluconazole (maintenance/secondary prophylaxis)",
          "route": "PO",
          "indication": "Long-term maintenance after consolidation (Cryptococcus); prevents relapse; continue until immune reconstitution (CD4 >100 for >3 months on ART with suppressed viral load)",
          "dosing": {
            "doseOptions": [
              {
                "text": "200 mg",
                "orderSentence": "Fluconazole (maintenance/secondary prophylaxis) 200 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "200 mg PO daily; continue for minimum 1 year; in HIV patients, continue until CD4 >100 for >3 months with suppressed viral load; in non-HIV, continue for 6-12 months minimum",
            "orderSentence": "Fluconazole (maintenance/secondary prophylaxis) 200 mg PO"
          },
          "pretreatment": "Completed consolidation phase; clinically stable",
          "contraindications": "Severe hepatic impairment; QT prolongation; pregnancy",
          "monitoring": "LFTs q3 months; CD4 count and viral load q3 months (HIV); clinical assessment for relapse symptoms",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Fluconazole (coccidioidal meningitis — lifelong)",
          "route": "PO",
          "indication": "LIFELONG therapy for coccidioidal meningitis; relapse rate near 80% if azole discontinued; never discontinue without ID specialist involvement",
          "dosing": {
            "doseOptions": [
              {
                "text": "400-800 mg",
                "orderSentence": "Fluconazole (coccidioidal meningitis — lifelong) 400-800 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "400 mg PO daily (standard); 800-1000 mg daily for refractory cases; LIFELONG treatment required — do NOT discontinue",
            "orderSentence": "Fluconazole (coccidioidal meningitis — lifelong) 400-800 mg PO"
          },
          "pretreatment": "Documented Coccidioides meningitis confirmed by CSF CF titer or culture",
          "contraindications": "Severe hepatic impairment; pregnancy",
          "monitoring": "LFTs q3 months; Coccidioides CF titers q3-6 months (declining indicates response); clinical assessment; bone density (long-term azole use)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Itraconazole (Histoplasma maintenance)",
          "route": "PO",
          "indication": "Maintenance therapy after amphotericin B induction for Histoplasma meningitis; minimum 12 months; longer if immunosuppressed",
          "dosing": {
            "doseOptions": [
              {
                "text": "200 mg",
                "orderSentence": "Itraconazole (Histoplasma maintenance) 200 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "200 mg PO BID-TID for minimum 12 months; itraconazole solution preferred (better absorption); take on empty stomach",
            "orderSentence": "Itraconazole (Histoplasma maintenance) 200 mg PO"
          },
          "pretreatment": "Completed amphotericin B induction (minimum 4-6 weeks for Histoplasma meningitis); clinical improvement",
          "contraindications": "Ventricular dysfunction; severe hepatic impairment; concurrent CYP3A4 substrates",
          "monitoring": "Itraconazole trough levels (target >1.0 mcg/mL); LFTs monthly; Histoplasma antigen q3 months (declining indicates response); cardiac function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Antiretroviral therapy (ART) — for HIV-associated fungal meningitis",
          "route": "PO",
          "indication": "DELAYED initiation in cryptococcal meningitis; starting ART too early increases IRIS risk and mortality; initiate 4-6 weeks after antifungal induction therapy",
          "dosing": {
            "doseOptions": [
              {
                "text": "Per HIV specialist",
                "orderSentence": "Antiretroviral therapy (ART) — for HIV-associated fungal meningitis Per HIV specialist PO"
              }
            ],
            "route": "PO",
            "instructions": "Initiate ART 4-6 WEEKS after starting antifungal therapy (NOT immediately); per COAT trial — early ART (within 1-2 weeks) increased mortality compared to delayed ART (4-6 weeks)",
            "orderSentence": "Antiretroviral therapy (ART) — for HIV-associated fungal meningitis Per HIV specialist PO"
          },
          "pretreatment": "Completed 2-week induction phase minimum; clinical stability; ICP controlled",
          "contraindications": "Do NOT start within 2 weeks of antifungal initiation (IRIS risk)",
          "monitoring": "CD4 count and viral load q3 months; IRIS symptoms (worsening headache, fever, meningismus, new focal deficits 2-8 weeks after ART initiation); LFTs; renal function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    },
    "Other Recommendations": {
      "Referrals & Consults": [
        {
          "item": "Infectious disease consultation for antifungal selection, treatment duration, and monitoring of drug levels and toxicity",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Neurology consultation for seizure management, elevated ICP assessment, and neurological monitoring",
          "ED": "URGENT",
          "HOSP": "URGENT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Neurosurgery consultation for VP shunt placement if refractory elevated ICP despite serial therapeutic LPs, or hydrocephalus requiring external ventricular drain",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "HIV/AIDS specialist referral for all HIV-positive patients for ART initiation timing (delayed 4-6 weeks), IRIS management, and long-term immunologic monitoring",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Critical care/ICU team for hemodynamic instability, respiratory failure, refractory elevated ICP, or rapidly declining neurological status",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Ophthalmology consultation for fundoscopic examination to assess papilledema (indicates elevated ICP); also screen for ocular cryptococcosis and coccidioidal choroiditis",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Pharmacy consultation for amphotericin B dosing, flucytosine level monitoring, azole drug interaction management, and renal dosing adjustments",
          "ED": "-",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Social work for discharge planning, medication access (antifungals are expensive), insurance assistance, and psychosocial support for prolonged treatment course",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Physical therapy for mobilization assessment and deconditioning prevention during prolonged hospitalization",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Palliative care for goals of care discussion in patients with severe disease, poor prognosis, or refractory infection",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "-",
          "ICU": "ROUTINE"
        }
      ],
      "Patient Instructions": [
        {
          "item": "Return to ED immediately if worsening headache, new or worsening confusion, vision changes, fever recurrence, neck stiffness, or seizure (may indicate rising ICP, treatment failure, or IRIS)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Do NOT stop antifungal medications without infectious disease physician guidance (premature discontinuation leads to relapse in >50% of cases)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Take fluconazole consistently at the same time each day to maintain therapeutic drug levels",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Report any new medications to infectious disease physician before starting (azoles have extensive drug interactions including with statins, certain cardiac drugs, and anticoagulants)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Avoid grapefruit and grapefruit juice while taking azole antifungals (increases azole levels via CYP3A4 inhibition)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Coccidioidal meningitis requires LIFELONG antifungal therapy — never stop medication even if feeling well (relapse rate >80% if discontinued)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "For HIV patients: take ART medications as prescribed without missing doses; report any worsening symptoms after starting ART (may indicate IRIS requiring treatment adjustment)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Attend all follow-up appointments including scheduled blood draws for drug level monitoring and liver function tests",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Use sun protection (sunscreen, protective clothing) while on voriconazole due to increased photosensitivity and long-term skin cancer risk",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Lifestyle & Prevention": [
        {
          "item": "Strict ART adherence for HIV-positive patients to achieve immune reconstitution and eventual discontinuation of fluconazole maintenance (CD4 >100 x 3 months with suppressed viral load)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Avoid soil disruption activities (digging, construction, archaeological excavation) in Coccidioides-endemic areas (southwestern US, Mexico, Central/South America) to reduce re-exposure risk",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Avoid bird/bat guano exposure, cave exploration, and demolition of old buildings in Histoplasma-endemic areas (Ohio/Mississippi River valleys)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Alcohol cessation during antifungal therapy to reduce hepatotoxicity risk and improve immune function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Adequate hydration (2-3 L water daily if tolerated) to support renal function during and after amphotericin B therapy",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Report any skin lesions, bone/joint pain, or pulmonary symptoms that may indicate disseminated fungal disease outside the CNS",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Women of childbearing age must use effective contraception during azole therapy (teratogenic — especially fluconazole at high doses and itraconazole)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Smoking cessation to improve immune function and reduce pulmonary infection risk",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    }
  },
  "differential": [
    {
      "diagnosis": "Bacterial meningitis",
      "features": "Acute onset (hours to days); high fever; toxic appearance; CSF: high WBC (>1000) with neutrophilic predominance; CSF glucose very low; positive Gram stain",
      "tests": "CSF cell count (neutrophils), Gram stain, bacterial culture, BioFire ME panel, procalcitonin (high), CSF lactate (>3.5)"
    },
    {
      "diagnosis": "Tuberculous (TB) meningitis",
      "features": "Subacute (weeks); basilar meningitis; cranial nerve palsies; CSF profile nearly identical to fungal (lymphocytic, low glucose, high protein); endemic exposure or HIV",
      "tests": "AFB smear and culture, TB PCR (GeneXpert), CSF adenosine deaminase (ADA >10), chest X-ray (miliary), QuantiFERON-TB Gold, brain MRI (basilar enhancement)"
    },
    {
      "diagnosis": "Viral meningitis",
      "features": "Acute onset; less toxic appearance; CSF: lymphocytic pleocytosis but NORMAL glucose (unlike fungal); protein mildly elevated; self-limited",
      "tests": "CSF glucose (normal in viral), BioFire ME panel (enterovirus, HSV-2), procalcitonin (low), CRP (mild)"
    },
    {
      "diagnosis": "HSV encephalitis",
      "features": "Acute; fever + confusion + seizures + focal deficits; temporal lobe predilection; encephalitis rather than meningitis",
      "tests": "MRI (temporal T2/FLAIR), CSF HSV PCR, EEG (PLEDs from temporal region)"
    },
    {
      "diagnosis": "Neurosyphilis",
      "features": "Chronic meningitis; cranial neuropathies; pupillary abnormalities (Argyll Robertson); CSF: lymphocytic with elevated protein",
      "tests": "Serum RPR/VDRL, CSF VDRL (specific but not sensitive), FTA-ABS, treponemal tests"
    },
    {
      "diagnosis": "Leptomeningeal carcinomatosis",
      "features": "Known malignancy; multiple cranial neuropathies; CSF: low glucose, elevated protein; positive cytology",
      "tests": "CSF cytology (repeat x3 for sensitivity); MRI with contrast (leptomeningeal enhancement); flow cytometry"
    },
    {
      "diagnosis": "Neurosarcoidosis",
      "features": "Chronic headache; cranial neuropathies (CN VII); hilar lymphadenopathy; elevated ACE",
      "tests": "Chest CT (hilar adenopathy); serum and CSF ACE; biopsy; PET-CT"
    },
    {
      "diagnosis": "Autoimmune/antibody-mediated encephalitis",
      "features": "Subacute; psychiatric symptoms; seizures; often young women; no fever initially",
      "tests": "Autoimmune antibody panel (serum + CSF); MRI; EEG; tumor screening"
    },
    {
      "diagnosis": "Drug-induced aseptic meningitis",
      "features": "NSAID, IVIG, TMP-SMX exposure; self-limited after drug withdrawal",
      "tests": "Drug history; CSF lymphocytic pleocytosis with sterile cultures; resolves with drug removal"
    },
    {
      "diagnosis": "Lymphocytic choriomeningitis virus (LCMV)",
      "features": "Rodent exposure; biphasic illness; meningitis with normal glucose",
      "tests": "LCMV serology (IgM); rodent exposure history"
    },
    {
      "diagnosis": "CNS lymphoma",
      "features": "Immunocompromised; periventricular enhancing lesions; elevated CSF protein; positive cytology or flow cytometry",
      "tests": "MRI (periventricular enhancement); CSF cytology; flow cytometry; brain biopsy"
    }
  ],
  "evidence": [
    {
      "recommendation": "Amphotericin B + flucytosine induction (2 weeks) as gold standard for cryptococcal meningitis",
      "evidenceLevel": "Class I, Level A",
      "source": "[Day et al. NEJM 2013 (ACTA trial)](https://pubmed.ncbi.nlm.nih.gov/23550668/); Perfect et al. CID 2010 (IDSA Guidelines)"
    },
    {
      "recommendation": "Liposomal amphotericin B preferred over conventional for reduced nephrotoxicity",
      "evidenceLevel": "Class I, Level A",
      "source": "Hamill et al. CID 2010 (AMBITION-cm); [Molloy et al. NEJM 2018 (AMBITION)](https://pubmed.ncbi.nlm.nih.gov/29539274/)"
    },
    {
      "recommendation": "Fluconazole 400 mg daily consolidation for 8 weeks, then 200 mg maintenance",
      "evidenceLevel": "Class I, Level A",
      "source": "Perfect et al. CID 2010 (IDSA Guidelines)"
    },
    {
      "recommendation": "Aggressive ICP management with serial therapeutic LPs reduces mortality in cryptococcal meningitis",
      "evidenceLevel": "Class I, Level B",
      "source": "[Graybill et al. CID 2000](https://pubmed.ncbi.nlm.nih.gov/11498404/); Perfect et al. CID 2010"
    },
    {
      "recommendation": "Delay ART by 4-6 weeks after antifungal initiation in HIV-associated cryptococcal meningitis to prevent IRIS",
      "evidenceLevel": "Class I, Level A",
      "source": "[Boulware et al. NEJM 2014 (COAT trial)](https://pubmed.ncbi.nlm.nih.gov/25229929/)"
    },
    {
      "recommendation": "Dexamethasone NOT recommended as routine adjunct in cryptococcal meningitis (increased mortality in ACTA trial)",
      "evidenceLevel": "Class I, Level A",
      "source": "[Beardsley et al. NEJM 2016 (ACTA dexamethasone)](https://pubmed.ncbi.nlm.nih.gov/27410934/)"
    },
    {
      "recommendation": "Serum and CSF CrAg (lateral flow assay) sensitivity >98% for cryptococcal meningitis",
      "evidenceLevel": "Class I, Level A",
      "source": "[Boulware et al. Emerg Infect Dis 2014](https://pubmed.ncbi.nlm.nih.gov/24378231/); [Rajasingham et al. Lancet Infect Dis 2017](https://pubmed.ncbi.nlm.nih.gov/28483415/)"
    },
    {
      "recommendation": "Lifelong fluconazole for coccidioidal meningitis (>80% relapse rate if discontinued)",
      "evidenceLevel": "Class I, Level B",
      "source": "[Galgiani et al. CID 2016 (IDSA Coccidioidomycosis Guidelines)](https://pubmed.ncbi.nlm.nih.gov/27470238/)"
    },
    {
      "recommendation": "Flucytosine drug level monitoring (peak 30-80 mcg/mL) to prevent myelosuppression",
      "evidenceLevel": "Class IIa, Level B",
      "source": "Perfect et al. CID 2010; Expert consensus"
    },
    {
      "recommendation": "Voriconazole as first-line for CNS aspergillosis with trough monitoring (2-5.5 mcg/mL)",
      "evidenceLevel": "Class I, Level B",
      "source": "[Patterson et al. CID 2016 (IDSA Aspergillosis Guidelines)](https://pubmed.ncbi.nlm.nih.gov/27365388/)"
    },
    {
      "recommendation": "WHO guidelines for cryptococcal meningitis management in resource-limited settings",
      "evidenceLevel": "Class I, Level A",
      "source": "[WHO Guidelines 2022](https://www.who.int/publications/i/item/9789240052178); [Loyse et al. Lancet Infect Dis 2013](https://pubmed.ncbi.nlm.nih.gov/23735626/)"
    },
    {
      "recommendation": "BioFire ME panel for rapid pathogen identification in meningitis",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[Leber et al. JCM 2016](https://pubmed.ncbi.nlm.nih.gov/27335149/)"
    },
    {
      "recommendation": "Histoplasma antigen testing (urine) highly sensitive for disseminated disease",
      "evidenceLevel": "Class I, Level B",
      "source": "[Wheat et al. CID 2007](https://pubmed.ncbi.nlm.nih.gov/19042679/)"
    },
    {
      "recommendation": "1,3-Beta-D-glucan as panfungal biomarker (not elevated in Cryptococcus or Mucorales)",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[Onishi et al. J Clin Microbiol 2012](https://pubmed.ncbi.nlm.nih.gov/22075593/)"
    },
    {
      "recommendation": "Intrathecal amphotericin B for refractory coccidioidal meningitis",
      "evidenceLevel": "Class IIb, Level C",
      "source": "Expert consensus; [Johnson & Einstein. Ann Intern Med 2007](https://pubmed.ncbi.nlm.nih.gov/17283349/)"
    },
    {
      "recommendation": "Immune reconstitution inflammatory syndrome (IRIS) management with corticosteroids",
      "evidenceLevel": "Class IIa, Level C",
      "source": "[Boulware et al. NEJM 2014](https://pubmed.ncbi.nlm.nih.gov/25229929/); Expert consensus"
    }
  ],
  "monitoring": [
    {
      "item": "Neurologic exam (GCS, mental status, cranial nerves)",
      "frequency": "q4h during induction; q8h during consolidation",
      "action": "If declining: STAT CT, repeat LP with opening pressure; reassess treatment",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Opening pressure (LP)",
      "frequency": "Daily therapeutic LP during induction if OP >25 cm H2O; then per clinical status",
      "action": "If persistently elevated: continue daily LPs; if refractory >1 week, consult neurosurgery for VP shunt",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Serum creatinine",
      "frequency": "Daily during amphotericin B induction; weekly during consolidation",
      "action": "If rising: increase pre-hydration; hold amphotericin if Cr >2x baseline; switch formulation; consider alternative regimen",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Potassium",
      "frequency": "Twice daily during amphotericin B; daily during consolidation",
      "action": "If low: aggressive IV/PO replacement; do NOT proceed with amphotericin until K >3.0",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Magnesium",
      "frequency": "Daily during amphotericin B; weekly during consolidation",
      "action": "If low: IV magnesium replacement; correct before treating hypokalemia (refractory K without Mg correction)",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "CBC with differential",
      "frequency": "Twice weekly during flucytosine therapy; weekly during consolidation",
      "action": "If cytopenias: check flucytosine level; hold if level >100 mcg/mL; consider dose reduction or discontinuation",
      "ED": "-",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Flucytosine drug level (peak)",
      "frequency": "3-5 days after initiation; after dose adjustments; after renal function changes",
      "action": "If >100: dose reduction or hold; recheck level; if <30: dose increase",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "-",
      "ICU": "ROUTINE"
    },
    {
      "item": "LFTs (AST, ALT, bilirubin, alk phos)",
      "frequency": "Weekly during induction and consolidation; monthly during maintenance",
      "action": "If >3x ULN: evaluate cause; consider dose reduction; if >5x ULN or symptomatic: hold azole and reassess",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "ROUTINE"
    },
    {
      "item": "Serum sodium",
      "frequency": "q6-8h during first 48h; then daily; q12h in ICU",
      "action": "If <130: SIADH evaluation; fluid restriction (1-1.2 L/day); if <120: 3% saline per sodium correction protocol",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "CSF fungal culture (repeat)",
      "frequency": "At 2 weeks (end of induction); if clinically indicated",
      "action": "If persistent positive culture: extend induction by 2 weeks; reassess regimen; consider salvage therapy",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Serum CrAg titer (serial)",
      "frequency": "Baseline; at 2 weeks; at end of consolidation; q3 months during maintenance",
      "action": "If rising or stable titer: reassess adherence; repeat LP; consider treatment failure; extend induction",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "CSF CrAg titer (serial)",
      "frequency": "At baseline; repeat LP at 2 weeks (end of induction)",
      "action": "If not declining: extend induction; reassess therapy",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "CD4 count and HIV viral load",
      "frequency": "At baseline; then q3 months (HIV patients)",
      "action": "If CD4 not recovering: assess ART adherence; optimize ART; cannot discontinue fluconazole maintenance until CD4 >100 x 3 months",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "IRIS surveillance (HIV patients)",
      "frequency": "Daily during first 2 weeks of ART; weekly for first 3 months",
      "action": "If worsening headache, fever, meningismus, new focal deficits: evaluate for IRIS vs treatment failure; may require steroids (dexamethasone) and therapeutic LP",
      "ED": "-",
      "HOSP": "STAT",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Coccidioides CF titer — CSF (if applicable)",
      "frequency": "At baseline; q3-6 months during treatment",
      "action": "If rising: treatment failure; increase fluconazole dose or switch therapy; ID consultation",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Temperature",
      "frequency": "q4h during induction; q8h during consolidation",
      "action": "If persistent fever >2 weeks: reassess treatment; repeat cultures; imaging for complications",
      "ED": "STAT",
      "HOSP": "STAT",
      "OPD": "-",
      "ICU": "STAT"
    },
    {
      "item": "Azole drug level (voriconazole, itraconazole)",
      "frequency": "At 5-7 days after initiation; after dose changes; q1-3 months long-term",
      "action": "If subtherapeutic: increase dose; check adherence; check drug interactions; if supratherapeutic: reduce dose",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    }
  ],
  "disposition": [
    {
      "disposition": "Discharge home",
      "criteria": "Completed induction (minimum 2 weeks); transitioned to oral consolidation (fluconazole); ICP controlled without need for daily LPs; neurologically stable; tolerating oral medications; reliable outpatient follow-up with ID and neurology; medication access confirmed; patient/family education on warning signs completed"
    },
    {
      "disposition": "Admit to floor (monitored)",
      "criteria": "Confirmed or suspected fungal meningitis requiring IV antifungal induction therapy; hemodynamically stable; GCS >=13; opening pressure manageable with intermittent (not daily) therapeutic LPs; no respiratory compromise"
    },
    {
      "disposition": "Admit to ICU",
      "criteria": "GCS <13 or rapidly declining consciousness; opening pressure >40 cm H2O refractory to therapeutic LP; need for EVD or ICP monitoring; respiratory failure requiring ventilatory support; septic shock; seizures (especially status epilepticus); severe electrolyte derangements from amphotericin B (refractory hypokalemia K <2.5); concurrent severe opportunistic infections in HIV/AIDS"
    },
    {
      "disposition": "Transfer to higher level",
      "criteria": "Need for neurosurgery (VP shunt, EVD) not available at current facility; need for ID specialist management of refractory fungal infection; need for neuro-ICU expertise for complex ICP management"
    },
    {
      "disposition": "Outpatient management (OPD)",
      "criteria": "Follow-up during consolidation and maintenance phases; serial CrAg titers q3 months; LFTs monthly then q3 months; CD4/viral load monitoring (HIV); medication adherence assessment; azole drug levels; coccidioidal meningitis patients require lifelong follow-up"
    }
  ]
}